Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urologic and Kidney Institute, Cleveland, Ohio 44195, USA.
Clin Cancer Res. 2010 Mar 1;16(5):1348-54. doi: 10.1158/1078-0432.CCR-09-2273. Epub 2010 Feb 23.
The emergence of viable therapeutic strategies in metastatic renal cell carcinoma has invigorated translational and clinical research in this disease. Building upon the clinical activity observed with inhibition of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways, novel strategies are being investigated to extend existing clinical benefits. Preclinical study has identified potential molecular mechanisms of response and resistance, providing a rational basis for biomarker development as well as sequential and combination therapy strategies. Several treatment strategies have emerged that are in the early phases of clinical testing. Further clinical and translational research is needed to validate initial hypotheses and translate observations into novel treatment strategies.
在转移性肾细胞癌中出现可行的治疗策略，激发了该疾病的转化和临床研究。在观察到血管内皮生长因子（VEGF）和哺乳动物雷帕霉素靶蛋白（mTOR）途径抑制的临床活性的基础上，正在研究新的策略以扩大现有的临床获益。临床前研究确定了潜在的反应和耐药分子机制，为生物标志物开发以及序贯和联合治疗策略提供了合理的依据。已经出现了几种处于临床测试早期阶段的治疗策略。需要进一步的临床和转化研究来验证初始假设，并将观察结果转化为新的治疗策略。
